Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01101945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Multi-Center, Long-Term Follow-up Study to Evaluate the Safety of PHX1149T in Subjects With Type 2 Diabetes Mellitus - Extension to Protocol PHX1149-PROT202
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.
Study identification
- NCT ID
- NCT01101945
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 339 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Dec 31, 2009
- Completion
- Feb 28, 2010
- Last update posted
- Aug 10, 2010
2007 – 2010
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fullerton | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Kissimmee | Florida | — | — |
| Not listed | Melbourne | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Gurnee | Illinois | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Henderson | Nevada | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Berlin | New Jersey | — | — |
| Not listed | Margate City | New Jersey | — | — |
| Not listed | Trenton | New Jersey | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Medford | Oregon | — | — |
| Not listed | Warminster | Pennsylvania | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01101945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2010 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01101945 live on ClinicalTrials.gov.